NASDAQ:ALNYAlnylam Pharmaceuticals Stock Price, Forecast & News

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALNY shares have increased by 25.2% and is now trading at $127.59. View which stocks have been most impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.62) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.89) by $0.27. The biopharmaceutical company earned $71.94 million during the quarter, compared to analyst estimates of $90.45 million. Alnylam Pharmaceuticals had a negative net margin of 310.01% and a negative return on equity of 57.63%. The firm's quarterly revenue was up 173.6% compared to the same quarter last year. During the same period last year, the firm posted ($1.42) earnings per share. View Alnylam Pharmaceuticals' earnings history.

18 brokers have issued 1-year target prices for Alnylam Pharmaceuticals' shares. Their forecasts range from $74.00 to $202.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $151.28 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price. View analysts' price targets for Alnylam Pharmaceuticals.

Media stories about ALNY stock have been trending extremely negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alnylam Pharmaceuticals earned a news impact score of -5.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutAlnylam Pharmaceuticals.

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), Opko Health (OPK), AbbVie (ABBV) and Vertex Pharmaceuticals (VRTX).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (10.70%), BlackRock Inc. (7.58%), Baillie Gifford & Co. (7.44%), State Street Corp (2.60%), Morgan Stanley (1.21%) and Morgan Stanley (1.21%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View institutional ownership trends for Alnylam Pharmaceuticals.

ALNY stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Maverick Capital Ltd., Rockefeller Capital Management L.P., Morgan Stanley, Morgan Stanley, Federated Hermes Inc., Pictet Asset Management Ltd., and Quantitative Investment Management LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet. View insider buying and selling activity for Alnylam Pharmaceuticals.

ALNY stock was bought by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , BlackRock Inc., Janus Henderson Group PLC, Sumitomo Mitsui Trust Holdings Inc., Duquesne Family Office LLC, First Trust Advisors LP, Baillie Gifford & Co., and Capital World Investors. View insider buying and selling activity for Alnylam Pharmaceuticals.

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALNY stock can currently be purchased for approximately $127.59.

Alnylam Pharmaceuticals has a market capitalization of $14.65 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,323 workers across the globe.

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]